Abstract 1776
Background
Mobile phones and tablets currently represent a significant presence in people’s everyday lives. They enable access to different information and services independent of current place and time. Such widespread connectivity offers significant potential in different app areas including health care. Advancements in mobile technology allow innovative data collection techniques such as measuring time use for the purpose of improving health behavior change interventions.
Methods
The aim of this study is to examine the usage rates of healthcare users and the health content of applications. A total of 707 mobile app were retrieved through a Google and App store for app published between January to April 2019. In this context, all applications were scanned using "cancer", "oncology", and "breast cancer" keywords on these stores. Repetitive applications were removed and research data was obtained. The applications were evaluated by considering their contents, developers and download numbers.
Results
In the Google play store, under the training title of 268 applications, it was found that 76 applications were used to maintain the treatment scheme and plan, and 12 were used for communication purposes. In the app store, it was determined that 235 applications were used for education, 102 for treatment plan and order, and 14 for communication purposes. Educational applications were used for journal, congress, student information, cancer guidelines and patient information. Drug management for treatment regimen and plan was determined to be related to radiological imaging, diet follow-up, symptoms, and nutrition. It was seen that communication applications were used for both patient-patient and physician-patient interaction. It was found that only 8% of the existing applications that the majority of the application developers did not have a healthcare staff established a health care staff.
Conclusions
It can be said that health personnel develop their own systems and provide accurate information to patients through these systems. With the advancement of health technologies, healthy results can be obtained in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract